Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 961 AL 975

Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease

Mosconi L, de Leon M, Murray J, E L, Lu J, Javier E, McHugh P, Swerdlow RH.

J Alzheimers Dis. 2011;27(3):483-90. doi: 10.3233/JAD-2011-110866.

Gender-dependent transthyretin modulation of brain amyloid-β levels: evidence from a mouse model of Alzheimer's disease

Oliveira SM, Ribeiro CA, Cardoso I, Saraiva MJ.

J Alzheimers Dis. 2011;27(2):429-39. doi: 10.3233/JAD-2011-110488.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease

Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E, Zaidi N, Pavlik V, Doody RS, Lyketsos CG.

J Alzheimers Dis. 2011;27(2):259-69. doi: 10.3233/JAD-2011-110405.

Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease

Bjerke M, Zetterberg H, Edman Å, Blennow K, Wallin A, Andreasson U.

J Alzheimers Dis. 2011;27(3):665-76. doi: 10.3233/JAD-2011-110566.

New diagnostic criteria for Alzheimer's disease

Zetterberg H.

Biomark Med. 2011 Aug;5(4):407-9. doi: 10.2217/bmm.11.46.

Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease

Lista S, Emanuele E.

Biomark Med. 2011 Aug;5(4):411-3. doi: 10.2217/bmm.11.50.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48.

Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond

Diniz BS, Teixeira AL.

Neuromolecular Med. 2011 Dec;13(4):217-22. doi: 10.1007/s12017-011-8154-x. Epub 2011 Sep 7.

[The role of CSF markers in the early diagnosis of Alzheimer's disease]

Vos SJ, Visser PJ, Verhey FR.

Tijdschr Psychiatr. 2011;53(9):647-53.

[Dementia: progress in diagnosis and treatment; Topics; V. Recent topics; 1. Biomarkers for Alzheimer's disease and other dementia]

Tokuda T.

Nihon Naika Gakkai Zasshi. 2011 Aug 10;100(8):2177-86. doi: 10.2169/naika.100.2177.

Rapidly progressive Alzheimer disease

Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I.

Arch Neurol. 2011 Sep;68(9):1124-30. doi: 10.1001/archneurol.2011.189.

Alzheimer's disease: implications of the updated diagnostic and research criteria

Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D.

J Clin Psychiatry. 2011 Sep;72(9):1190-6. doi: 10.4088/JCP.10087co1c.

Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease

Jawhar S, Wirths O, Bayer TA.

J Biol Chem. 2011 Nov 11;286(45):38825-32. doi: 10.1074/jbc.R111.288308. Epub 2011 Sep 29.

Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study

Zuliani G, Donnorso MP, Bosi C, Passaro A, Dalla Nora E, Zurlo A, Bonetti F, Mozzi AF, Cortese C.

BMC Neurol. 2011 Oct 4;11:121. doi: 10.1186/1471-2377-11-121.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias